Objective
GAT Biosciences (GATBIO) is a women-led Biotech SME targeting the exploitation of its proprietary GRTTM technology as a novel solution for the development and production of complex biologic drugs for biopharma and veterinary markets. Specifically, we are developing a game-changer next generation of accessible and non-invasive (oral, topic, inhaled) biopharmaceuticals through proprietary and sustainable microalgae biofactories.
Our first candidate for the biopharmaceutical Market, GB-AF-004, will enter pre-clinical demonstration in 2023. GB-AF-004 is an anti-inflammatory biologic for the oral treatment of Inflammatory Bowel Diseases and Disorders (IBDs). The term IBDs includes a range of chronic and painful autoimmune diseases affecting localy the intestine, affecting patients from their youth and throughout life and of unknown causess. More than 6 million people are affected by IBDs globally and their global treatment market is estimated by 2029 at 37 billion euros per year. GB-AF-004 has the potential to be a game-changer in the treatment of this high prevalence and chronic inflammatory intestinal diseases.
GATBIO has been recently granted a Seal of Excellence from the EIC accelerator Program supporting disruptive European SMEs for their acceleration to the market. The related funding will allow us to enter the preclinical development of GB-AF-004 early in 2023. In this frame, additional support related not to scientific development per se but to reinforcing our strategic business management and vision could be key to success in our next steps and culminate GB-AF-004 out-licensing. Specifically, to access Expert mentoring and Biomed advice related to i) clinical positioning in the IBD market and ii) out-licensing strategy, would be key to success in the arrival of our 1st candidate to the regulated market and would translate into GATBIO’s consolidation and exponential growth based on innovation out-licensing.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.3.2 - European innovation ecosystems
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-CSA - HORIZON Coordination and Support Actions
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-EIE-2022-SCALEUP-02
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
08028 Barcelona
Spain
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.